Hepatitis C-virus (HCV) antibodies in patients after kidney transplantation.
The hepatitis C-virus (HCV) is the main etiologic agent of posttransfusion hepatitis (PTH). Most patients depending on hemodialysis need transfusion of blood before kidney transplantation. Of 272 patients after kidney transplantation, 27 (10%) were found to be anti-HCV-ELISA-positive (HCV-Antibody-ELISA, Ortho Diagnostics). The antibodies could be neutralized by HCV C-100-3 antigen. Eight of 22 patients (36%) who had more than one kidney transplantation were classified anti-HCV positive [30% (8/27) of all anti-HCV positive patients]. The number of transfused blood units ranged from 0 to 99 BU. Receiving more than one kidney graft or the transfusion of more than 5 units of blood increased the risk for HCV infection 3.5 or 4.1 times, respectively, compared with one transplantation or less than 5 units of blood. No significant interactions were seen between these two variables. Of the anti-HCV positive patients, 48% were anti-HBc negative as well as HBs-antigen negative, 52% were anti-HBc positive.
Baur
P
P
Institute of Immunology and Serology, Ruprecht-Karls-University, Heidelberg, Federal Republic of Germany.
Daniel
V
V
Pomer
S
S
Scheurlen
H
H
Opelz
G
G
Roelcke
D
D
D000328:Adult; D001803:Blood Transfusion; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000635:transmission*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D012044:Regression Analysis; D006435:Renal Dialysis; D012307:Risk Factors
D006508:Hepatitis Antibodies